---
title: 'Industry Daily Summary: What Happened on October 18, 2026'
headline: Liquidia settles six lawsuits with United Therapeutics for $380.7 million
description: Liquidia will stop promoting Yutrepia for PH-ILD in new patients but
can keep selling it for PAH and developing it for other uses.
url: https://thebench.bio/news/industry/2026-10-18
topic: industry
date: '2026-10-18'
covers:
- '2026-10-18'
date_published: '2026-10-19T00:01:25Z'
date_modified: '2026-10-19T00:01:25Z'
tags:
- Industry
sources: 1
publisher: TheBench.Bio
---
# Industry Daily Summary: What Happened on October 18, 2026
**Liquidia settles six lawsuits with United Therapeutics for $380.7 million**
Liquidia will stop promoting Yutrepia for PH-ILD in new patients but can keep selling it for PAH and developing it for other uses.
## Today in brief
Liquidia will pay United Therapeutics and other parties $380.7 million and remove Yutrepia’s PH-ILD indication for new patients as part of a settlement resolving six lawsuits. [1] The agreement preserves Yutrepia sales for PAH and lets Liquidia continue developing L606 for PH-ILD and PAH with Pharmosa Biopharm. [1]
## Liquidia gives up Yutrepia’s PH-ILD label in legal settlement
The settlement resolves six disputes involving patent, trade-secret and antitrust claims. [1] Liquidia agreed not to challenge a court ruling that found it infringed two claims in a United Therapeutics patent. [1]
Liquidia will pay United Therapeutics $175 million by October 30, with possible extensions, followed by two payments of $72.7 million in 2027. [1] It will also pay $60.3 million to parties with interests in a treprostinil-injection antitrust case and end its promotional arrangement for that product. [1]
Yutrepia can remain on the market for PAH, and Liquidia can develop it for uses other than PH-ILD, including Raynaud’s phenomenon associated with systemic sclerosis. [1] Liquidia can also continue developing L606 for PH-ILD and PAH with Pharmosa Biopharm. [1]
Liquidia reported unaudited third-quarter Yutrepia sales of $222.7 million, up 31% from the second quarter. [1] Executives said PAH accounted for 60% of sales, with the share trending toward 70%. [1] Liquidia expects Yutrepia to exceed $1 billion in annual sales by 2028. [1] United Therapeutics said it offered a settlement that would have kept Yutrepia available to PH-ILD patients, but Liquidia declined. [1]
## The day in numbers
- **$380.7 million**: Total settlement payments Liquidia agreed to make. [1]
- **$222.7 million**: Unaudited Yutrepia sales in the third quarter, up 31% from the second quarter. [1]
## Also published
- [The Antibiotics Exist —The System Cannot Deliver Them](), MedCity News
## Sources
1. [StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics](), GEN, 2026-10-18
---
TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.
[1]: